TY - JOUR
T1 - Pegylated leptin antagonist is a potent orexigenic agent
T2 - Preparation and mechanism of activity
AU - Elinav, Eran
AU - Niv-Spector, Leonora
AU - Katz, Meirav
AU - Price, Tulin O.
AU - Ali, Mohammed
AU - Yacobovitz, Michal
AU - Solomon, Gili
AU - Reicher, Shay
AU - Lynch, Jessica L.
AU - Halpern, Zamir
AU - Banks, William A.
AU - Gertler, Arieh
PY - 2009/7
Y1 - 2009/7
N2 - Leptin, a pleiotropic adipokine, is a central regulator of appetite and weight and a key immunomodulatory protein. Although inborn leptin deficiency causes weight gain, it is unclear whether induced leptin deficiency in adult wild-type animals would be orexigenic. Previous work with a potent competitive leptin antagonist did not induce a true metabolic state of leptin deficiency in mice because of a short circulating half-life. In this study, we increased the half-life of the leptin antagonist by pegylation, which resulted in significantly increased bioavailability and retaining of antagonistic activity. Mice administered the pegylated antagonist showed a rapid and dramatic increase in food intake with weight gain. Resulting fat was confined to the mesenteric region with no accumulation in the liver. Serum cholesterol, triglyceride, and hepatic aminotransferases remained unaffected. Weight changes were reversible on cessation of leptin antagonist treatment. The mechanism of severe central leptin deficiency was found to be primarily caused by blockade of transport of circulating leptin across the blood-brain barrier with antagonisms at the arcuate nucleus playing amoreminor role. Altogetherweintroduce a novelcompoundthat induces central and peripheral leptin deficiency. This compound should be useful in exploring the involvement of leptin in metabolic and immune processes and could serve as a therapeutic for the treatment of cachexia.
AB - Leptin, a pleiotropic adipokine, is a central regulator of appetite and weight and a key immunomodulatory protein. Although inborn leptin deficiency causes weight gain, it is unclear whether induced leptin deficiency in adult wild-type animals would be orexigenic. Previous work with a potent competitive leptin antagonist did not induce a true metabolic state of leptin deficiency in mice because of a short circulating half-life. In this study, we increased the half-life of the leptin antagonist by pegylation, which resulted in significantly increased bioavailability and retaining of antagonistic activity. Mice administered the pegylated antagonist showed a rapid and dramatic increase in food intake with weight gain. Resulting fat was confined to the mesenteric region with no accumulation in the liver. Serum cholesterol, triglyceride, and hepatic aminotransferases remained unaffected. Weight changes were reversible on cessation of leptin antagonist treatment. The mechanism of severe central leptin deficiency was found to be primarily caused by blockade of transport of circulating leptin across the blood-brain barrier with antagonisms at the arcuate nucleus playing amoreminor role. Altogetherweintroduce a novelcompoundthat induces central and peripheral leptin deficiency. This compound should be useful in exploring the involvement of leptin in metabolic and immune processes and could serve as a therapeutic for the treatment of cachexia.
UR - http://www.scopus.com/inward/record.url?scp=67649665611&partnerID=8YFLogxK
U2 - 10.1210/en.2008-1706
DO - 10.1210/en.2008-1706
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 19342450
AN - SCOPUS:67649665611
SN - 0013-7227
VL - 150
SP - 3083
EP - 3091
JO - Endocrinology
JF - Endocrinology
IS - 7
ER -